PrADDYI® (flibanserin) Pharmacist's Checklist

Prior to dispensing ADDYI (flibanserin) the pharmacist should consider using the Pharmacist's Checklist as a tool to confirm the patient's eligibility for treatment.

Pr addyi® (flibanserin) 100mg tablets

About ADDYI

ADDYI is indicated for the treatment of premenopausal and naturally postmenopausal women ≤ 60 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire for a minimum of 6 months, which occurs 75-100% of the time, causes marked distress or interpersonal difficulty and is NOT due to:

- A co-existing medical or psychiatric condition,
- Problems within the relationship, or
- The effects of a medication or other drug substance.

The Pharmacist should distribute the patient medication information at the time of dispensing ADDYI.

Important instructions when dispensing ADDYI:
ADDYI should not be dispensed to any patients with a YES response to the questions below.
If "YES" please contact prescriber for confirmation of the appropriateness of dispensing.

1. Is patient pregnant or breastfeeding?	◯ Yes	◯ No
2. Is patient taking any moderate or strong CYP3A4 inhibitors? Some examples of moderate or strong CYP3A4 inhibitors include: ritonavir, flucanozole, ciprofloxacin, erythromycin, boceprevir, nefazodone and grapefruit juice. Please consult the ADDYI Product Monograph for additional guidance.	◯ Yes	◯ No
3. Does patient have hypersensitivity to flibanserin or other components of ADDYI?	◯ Yes	◯ No
4. Does patient take P-glycoprotein (P-gp) substrates (digoxin)?	◯ Yes	◯ No

Patient counseling for safe use of ADDYI:
Patients should be counseled on how to take ADDYI to promote safe use of the medication.

1. ADDYI is dosed at bedtime because administration during waking hours increases the risks of hypotension, syncope, and CNS depression (such as somnolence and sedation).	◯ Completed
2. The importance of limiting their alcohol intake in combination with ADDYI, as the combination of ADDYI and alcohol may increase the risk of severe low blood pressure.	◯ Completed
3. The patient should be discouraged from driving, operating machinery or engaging in activities that require clear thinking until 6 hours after taking ADDYI and until they know how it may affect them.	◯ Completed
4. If patient misses a dose, they should be instructed to skip that dose and take their next dose at bedtime of the following day. Increased doses are not associated with greater effect and can increase the risks of side effects.	◯ Completed
5. Patient should be cautioned that not all women benefit from treatment with ADDYI. Treatment should be discontinued after 8 weeks if there has been no improvement.	◯ Completed

For additional information please consult the ADDYI Product Monograph

SEARCHLIGHT PHARMA

Searchlight Pharma Inc.
1600 Notre Dame St. West, Suite 312
Montréal, Québec H3J 1M1
www.searchlightpharma.com

REVIEWED BY PAAB